The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 21, 2021

Filed:

Apr. 25, 2018
Applicant:

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Inventors:

Yangbing Zhao, Lumberton, NJ (US);

Jiangtao Ren, Philadelphia, PA (US);

Xiaojun Liu, Wallingford, PA (US);

Carl H. June, Merion Station, PA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/26 (2015.01); C12N 15/113 (2010.01); C12N 15/85 (2006.01); A61K 39/00 (2006.01); A61P 37/06 (2006.01); A61P 35/00 (2006.01); A61K 35/17 (2015.01);
U.S. Cl.
CPC ...
C12N 15/1138 (2013.01); A61K 35/17 (2013.01); A61K 35/26 (2013.01); A61K 39/001102 (2018.08); A61P 35/00 (2018.01); A61P 37/06 (2018.01); C12N 15/85 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C12N 2310/10 (2013.01); C12N 2310/20 (2017.05); C12N 2501/48 (2013.01); C12N 2501/515 (2013.01); C12N 2501/599 (2013.01); C12N 2501/998 (2013.01); C12N 2510/00 (2013.01);
Abstract

The present invention relates to compositions and methods for generating a modified T cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of TCR α chain, TCR β chain, beta-2 microglobulin and FAS further comprising a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (CAR). Also included are methods and pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as an autoimmune disease.


Find Patent Forward Citations

Loading…